240nok
-4,0 %
Date:2024-05-02Time:17:30:00Latest report:Q4-2022List:Oslo BorsTicker:CRNA
Market Cap:20 mnokEnterprise Value:16 mnokNet Sales:- mnokEarnings:-102,5 mnokEmployees:0ISIN:NO0013033795

Ratios

10-year key figure history for Circio turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Circio with index and moving average MA50 and MA200.

Stockprice:2,40
MA50:5,29
MA200:8,95
Price/MA200:-73,2 %
RSI (14):25,1
Price/MA50:-54,6 %

Description

Targovax ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing highly targeted immunotherapy treatments for cancer patients.

Biotechnology